Ned Milenkovich

EpiPen Maker Strikes Deal with DOJIn October 2016 Mylan N.V. announced that its subsidiary, Mylan Inc., agreed to pay a $465 million settlement to the U.S. Department of Justice (DOJ) to resolve questions surrounding the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector (EpiPen) for the Medicaid Drug Rebate Program.
New CMS Proposed Rule Expands Medicare Reimbursement For Telehealth ServicesThe Centers for Medicare and Medicaid Services (CMS) has once again released its Physician Fee Schedule Proposed Rule for Calendar Year 2017.
Employees pose greatest threat to PHI securityLast week, Grace Hospital in Winnipeg fired a pharmacist because the healthcare worker had allegedly accessed patient health information from 56 hospital patients, just “out of curiosity,” according to a report in the Winnipeg Sun.
Burgess, Milenkovich elected to new posts; Plagakis ends a long runThe latest Drug Topics news.
OIG warns pharmacies about drugmaker coupons used in claims to federal payersPharmacies that accept copayment coupons should take immediate steps to address the issues raised by OIG.
HIPAA business associate agreements: Update deadline approachesHealthcare providers who share HIPAA-protected health information with certain service providers must update their written agreements by September 22, 2014.
Milenkovich joins Roetzel & AndressDrug Topics’ legal compliance columnist named partner in Roetzel's Chicago office and head of the firm’s Drug and Pharmacy practice.
Federal track and trace legislation imminentThe bicameral legislation provides specific requirements for all stakeholders in the drug-distribution supply chain, including manufacturers, wholesalers, repackagers, and pharmacies.
Compounding pharmacies bring health plan lawsuitMassachusetts' Harvard Pilgrim Health Care has instituted a policy shift excluding coverage of prescription drugs compounded for adults. Plaintiffs call this "a callous decision" and "a major blow" to the state's many patients who depend on compounded medications.
Emergency contraceptive’s curious path to OTC
Emergency contraceptive’s curious path to OTCIn June 2013, the Department of Justice under the Obama administration announced an end to its lawsuits regarding age restrictions on “Plan B One-Step” (levonorgestrel), the morning-after pill. The DOJ decided not to appeal the ruling by Judge Edward Korman of the District Court of Eastern New York.